BCL-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland

S. Pilotti, P. Collini, F. Rilke, G. Cattoretti, R. Del Bo, M. A. Pierotti

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

The bcl-2 product has been related to the block of programmed cell death (apoptosis) both in lymphoid and in epithelial cells. The pathological expression of bcl-2 has been investigated mainly in haematological malignancies. Here we have investigated bcl-2 expression in a model of epithelial tumours represented by the spectrum of carcinomas arising from the follicular epithelium of the human thyroid gland. The analysis was carried out by immunocytochemistry on archival material using monoclonal antibodies against bcl-2 and thyroglobulin (Tg) on consecutive sections of 94 well- differentiated carcinomas (WDCs), 19 poorly differentiated carcinomas (PDCs), and 22 undifferentiated carcinomas (UCs) of the thyroid gland. In a subset of 5 cases of UC showing a differentiated component (UC-D), the expression of p53 protein was also investigated. As controls, fetal and adult normal thyroid glands and adenomas were analysed. bcl-2 expression was detected in 74 of 94 cases (78·7 per cent) of WDC, 16 of 19 cases (84·2 per cent) of PDC, and 3 of 22 cases (13·6 per cent) of UC. Simultaneous expression of bcl-2 protein and Tg was observed in 74 of 94 cases (78·7 per cent) of WDC, 13 of 19 cases (68·4 per cent) of PDC, and in no case of UC. bcl-2 and Tg immunostaining was detected in all fetal and normal thyroid glands as well as in the adenoma specimens examined. In the subset of UC-D, mutual exclusion of bcl-2 and p53 expression was observed in the undifferentiated and differentiated components (p53 but not bcl-2 expressed in the former). Our data indicate that within the spectrum of thyroid carcinomas bcl-2 expression, similarly to Tg, is strictly correlated with cell differentiation and that its abrogation is restricted to UCs, in which alterations of the p53 gene represent a late genetic event related to tumour progression.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalJournal of Pathology
Volume172
Issue number4
DOIs
Publication statusPublished - 1994

Fingerprint

Thyroid Gland
Epithelium
Carcinoma
Proteins
Thyroglobulin
Thyroid Neoplasms
p53 Genes
Hematologic Neoplasms
Adenoma
Cell Differentiation
Neoplasms
Cell Death
Epithelial Cells
Immunohistochemistry
Monoclonal Antibodies
Apoptosis

Keywords

  • bcl-2
  • dedifferentiation
  • immunocytochemistry
  • p53
  • thyroid carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

BCL-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. / Pilotti, S.; Collini, P.; Rilke, F.; Cattoretti, G.; Del Bo, R.; Pierotti, M. A.

In: Journal of Pathology, Vol. 172, No. 4, 1994, p. 337-342.

Research output: Contribution to journalArticle

Pilotti, S. ; Collini, P. ; Rilke, F. ; Cattoretti, G. ; Del Bo, R. ; Pierotti, M. A. / BCL-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. In: Journal of Pathology. 1994 ; Vol. 172, No. 4. pp. 337-342.
@article{88fddb9aca5b47eeb7f515e3a2e354f9,
title = "BCL-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland",
abstract = "The bcl-2 product has been related to the block of programmed cell death (apoptosis) both in lymphoid and in epithelial cells. The pathological expression of bcl-2 has been investigated mainly in haematological malignancies. Here we have investigated bcl-2 expression in a model of epithelial tumours represented by the spectrum of carcinomas arising from the follicular epithelium of the human thyroid gland. The analysis was carried out by immunocytochemistry on archival material using monoclonal antibodies against bcl-2 and thyroglobulin (Tg) on consecutive sections of 94 well- differentiated carcinomas (WDCs), 19 poorly differentiated carcinomas (PDCs), and 22 undifferentiated carcinomas (UCs) of the thyroid gland. In a subset of 5 cases of UC showing a differentiated component (UC-D), the expression of p53 protein was also investigated. As controls, fetal and adult normal thyroid glands and adenomas were analysed. bcl-2 expression was detected in 74 of 94 cases (78·7 per cent) of WDC, 16 of 19 cases (84·2 per cent) of PDC, and 3 of 22 cases (13·6 per cent) of UC. Simultaneous expression of bcl-2 protein and Tg was observed in 74 of 94 cases (78·7 per cent) of WDC, 13 of 19 cases (68·4 per cent) of PDC, and in no case of UC. bcl-2 and Tg immunostaining was detected in all fetal and normal thyroid glands as well as in the adenoma specimens examined. In the subset of UC-D, mutual exclusion of bcl-2 and p53 expression was observed in the undifferentiated and differentiated components (p53 but not bcl-2 expressed in the former). Our data indicate that within the spectrum of thyroid carcinomas bcl-2 expression, similarly to Tg, is strictly correlated with cell differentiation and that its abrogation is restricted to UCs, in which alterations of the p53 gene represent a late genetic event related to tumour progression.",
keywords = "bcl-2, dedifferentiation, immunocytochemistry, p53, thyroid carcinoma",
author = "S. Pilotti and P. Collini and F. Rilke and G. Cattoretti and {Del Bo}, R. and Pierotti, {M. A.}",
year = "1994",
doi = "10.1002/path.1711720408",
language = "English",
volume = "172",
pages = "337--342",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - BCL-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland

AU - Pilotti, S.

AU - Collini, P.

AU - Rilke, F.

AU - Cattoretti, G.

AU - Del Bo, R.

AU - Pierotti, M. A.

PY - 1994

Y1 - 1994

N2 - The bcl-2 product has been related to the block of programmed cell death (apoptosis) both in lymphoid and in epithelial cells. The pathological expression of bcl-2 has been investigated mainly in haematological malignancies. Here we have investigated bcl-2 expression in a model of epithelial tumours represented by the spectrum of carcinomas arising from the follicular epithelium of the human thyroid gland. The analysis was carried out by immunocytochemistry on archival material using monoclonal antibodies against bcl-2 and thyroglobulin (Tg) on consecutive sections of 94 well- differentiated carcinomas (WDCs), 19 poorly differentiated carcinomas (PDCs), and 22 undifferentiated carcinomas (UCs) of the thyroid gland. In a subset of 5 cases of UC showing a differentiated component (UC-D), the expression of p53 protein was also investigated. As controls, fetal and adult normal thyroid glands and adenomas were analysed. bcl-2 expression was detected in 74 of 94 cases (78·7 per cent) of WDC, 16 of 19 cases (84·2 per cent) of PDC, and 3 of 22 cases (13·6 per cent) of UC. Simultaneous expression of bcl-2 protein and Tg was observed in 74 of 94 cases (78·7 per cent) of WDC, 13 of 19 cases (68·4 per cent) of PDC, and in no case of UC. bcl-2 and Tg immunostaining was detected in all fetal and normal thyroid glands as well as in the adenoma specimens examined. In the subset of UC-D, mutual exclusion of bcl-2 and p53 expression was observed in the undifferentiated and differentiated components (p53 but not bcl-2 expressed in the former). Our data indicate that within the spectrum of thyroid carcinomas bcl-2 expression, similarly to Tg, is strictly correlated with cell differentiation and that its abrogation is restricted to UCs, in which alterations of the p53 gene represent a late genetic event related to tumour progression.

AB - The bcl-2 product has been related to the block of programmed cell death (apoptosis) both in lymphoid and in epithelial cells. The pathological expression of bcl-2 has been investigated mainly in haematological malignancies. Here we have investigated bcl-2 expression in a model of epithelial tumours represented by the spectrum of carcinomas arising from the follicular epithelium of the human thyroid gland. The analysis was carried out by immunocytochemistry on archival material using monoclonal antibodies against bcl-2 and thyroglobulin (Tg) on consecutive sections of 94 well- differentiated carcinomas (WDCs), 19 poorly differentiated carcinomas (PDCs), and 22 undifferentiated carcinomas (UCs) of the thyroid gland. In a subset of 5 cases of UC showing a differentiated component (UC-D), the expression of p53 protein was also investigated. As controls, fetal and adult normal thyroid glands and adenomas were analysed. bcl-2 expression was detected in 74 of 94 cases (78·7 per cent) of WDC, 16 of 19 cases (84·2 per cent) of PDC, and 3 of 22 cases (13·6 per cent) of UC. Simultaneous expression of bcl-2 protein and Tg was observed in 74 of 94 cases (78·7 per cent) of WDC, 13 of 19 cases (68·4 per cent) of PDC, and in no case of UC. bcl-2 and Tg immunostaining was detected in all fetal and normal thyroid glands as well as in the adenoma specimens examined. In the subset of UC-D, mutual exclusion of bcl-2 and p53 expression was observed in the undifferentiated and differentiated components (p53 but not bcl-2 expressed in the former). Our data indicate that within the spectrum of thyroid carcinomas bcl-2 expression, similarly to Tg, is strictly correlated with cell differentiation and that its abrogation is restricted to UCs, in which alterations of the p53 gene represent a late genetic event related to tumour progression.

KW - bcl-2

KW - dedifferentiation

KW - immunocytochemistry

KW - p53

KW - thyroid carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028174254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028174254&partnerID=8YFLogxK

U2 - 10.1002/path.1711720408

DO - 10.1002/path.1711720408

M3 - Article

VL - 172

SP - 337

EP - 342

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -